Dark

Check out our Dark Pool Levels

ESALF
EISAI CO LTD
stock OTC

Inactive

Feb 23, 2021

71.51USD-2.641%(-1.94)100

Pre-market

0.00USD-100.000%(-73.45)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 16, 2021

12:12PM EST Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026 Benzinga

Nov 30, 2021

04:02PM EST Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma Benzinga

Nov 11, 2021

12:58PM EST Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial Benzinga

Sep 28, 2021

09:19AM EDT Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug Benzinga

Sep 7, 2021

06:57AM EDT Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma Benzinga

Aug 30, 2021

03:51PM EDT Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free Benzinga

Aug 20, 2021

04:37PM EDT White House Dismisses Janet Woodcock As Permanent FDA Commissioner Candidate: Bloomberg Benzinga

Aug 17, 2021

01:14PM EDT Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's Benzinga

Aug 12, 2021

07:53AM EDT Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs Benzinga

Jul 30, 2021

12:31PM EDT Biogen - Eisai Launch 5-Year Study To See How Well Alzheimer's Drug Aduhelm Works In Real World Benzinga

Jul 27, 2021

06:30AM EDT Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients Benzinga

Jul 15, 2021

10:51AM EDT Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News Benzinga

Jun 18, 2021

07:05AM EDT Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights Benzinga

Jun 7, 2021

09:48AM EDT Merck/Eisai's Keytruda-Lenvima Combo Results in Better Health-Related Quality of Life Measures Compared to Sunitinib Benzinga

Jun 4, 2021

03:55PM EDT Ahead Of Judgement Day, FDA Faces Test with Biogen's Alzheimer's Drug Decision Benzinga

Mar 19, 2021

09:16AM EDT Merck' Keytruda Plus Eisai's Lenvima Cuts Risk Of Death By 38% In Endometrial Cancer Trial Compared To Chemo Benzinga

Feb 16, 2021

01:19PM EST Merck/Eisai's Keytruda-Lenvima Combo Tops Standard Of Care In Late-Stage Kidney Cancer Study Benzinga

Share